Original ContributionProlonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible
References (44)
- et al.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial
Lancet
(2007) - et al.
Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199
Breast Cancer Res Treat
(2005) - et al.
Adjuvant docetaxel for node-positive breast cancer
N Engl J Med
(2005) - et al.
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer
J Clin Oncol
(2006) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial
J Clin Oncol
(2001)- et al.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
N Engl J Med
(2006) - et al.
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
N Engl J Med
(2007) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials
Lancet
(2005)- et al.
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
Cancer
(1983) - et al.
Prognostic factors in breast cancer
Sem Surg Oncol
(1989)
Cytokinetics
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial
J Clin Oncol
(2003)
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial
J Clin Oncol
(2001)
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
J Clin Oncol
(2003)
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP-B 28
J Clin Oncol
(2005)
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group MA.5
J Clin Oncol
(2005)
Sequential adjuvant epirubicinbased and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial
J Clin Oncol
(2006)
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
J Natl Cancer Inst
(2008)
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
J Clin Oncol
(1986)
Use of in vitro dose-response effect to select antineoplastics for high-dose or regional administration regimens
J Clin Oncol
(1986)
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22
J Clin Oncol
(1997)
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
J Clin Oncol
(1999)
Cited by (0)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2008 Elsevier Inc. All rights reserved.